Dr. Roman Perez-Soler on Treating NSCLC After First-Line Treatments

Special ReportsNSCLC (Issue 9)
Volume 9
Issue 4

Roman Perez-Soler, MD, talks about NSCLC tumors becoming resistance to chemotherapy and first-line treatment.

Roman Perez-Soler, MD, chairman and chief, department of medical oncology, Montefiore Medical Center, deputy director, Albert Einstein Cancer Center, talks about non-small cell lung cancer (NSCLC) tumors becoming resistant to chemotherapy and first-line treatment. 

Perez-Soler says that usually NSCLC tumors become resistant within 2 to 3 months, or grow back with a resistance to the same drug initially used as treatment. He adds that once that occurs, it could be time to switch to immunotherapies, which he believes could also be an effective front-line treatment by themselves or with chemotherapies due to their low toxicities.

Related Videos
Expert on NSCLC
Expert on NSCLC
Expert on NSCLC
Related Content